Neurocrine Is Maintained at Buy by UBS
Neurocrine Biosciences Analyst Ratings
Express News | Neurocrine Biosciences Inc : UBS Raises Target Price to $162 From $142
UBS Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Cuts Target Price to $162
Neurocrine Biosciences Announces Publication on Traditional Glucocorticoid Treatment in Classic Congenital Adrenal Hyperplasia in Expert Review of Endocrinology & Metabolism
RBC Capital Maintains Neurocrine Biosciences(NBIX.US) With Hold Rating, Raises Target Price to $159
Just Care Bears : I thought there’s a FDA approval going on on this today no news yet
Claudius NJIE Just Care Bears : yes good news is coming.
Claudius NJIE : pls run to at least 50
Srav Reddy : You missed VSTM and